ClinicalTrials.gg
Active, not recruitingNCT04428944STARAF3Updated May 8, 2026

STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation

An interventional study of Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI) and Pulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers) in Atrial Fibrillation, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Active, not recruiting at 32 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
617
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 318 studies in Atrial Fibrillation with a site in Canada — 50 open to participants now, 73 under way, 8 of them phase 3. Atrial Fibrillation · Canada.

Enrollment
75th of 261
617 · median 282
Started
2021
with 14 others
No phase
135 of 318
28 open now
Primary completion
2027-09
later than 35 of 72 live
Registered
230th of 318
by date

Among the 318 studies in Atrial Fibrillation with a site in Canada, this one is the 75th largest by enrollment of the 261 interventional ones that give a count, is one of 15 that started in 2021, is one of 135 with no phase, reaches primary completion later than 35 of the 72 other live ones, and was the 230th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

50 of the 318 studies in Atrial Fibrillation with a site in Canada are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 318 studies in Atrial Fibrillation with a site in Canada, or all of them as a file.
02

Study summary

The objective of this study is to compare the efficacy of three different ablation strategies in patients with persistent AF:

  1. PV antral isolation alone (PVAI)
  2. PV antral isolation plus ablation of drivers (PVAI+drivers)
  3. PV antral isolation plus isolation of posterior wall (PVAI+box) All three strategies will employ contemporary catheter ablation technology using more efficient open irrigated tip cooling and contact force sensing.
03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • ablation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients 18 years of age or older
  2. Patients undergoing first-time ablation procedure for AF
  3. Patients with persistent AF defined as a sustained episode more than 3 months but less than three years
  4. Patients with symptomatic AF - symptomatic patients are those who have been aware of their AF at any time within the last 5 years prior to enrolment. Symptoms may include, but are not restricted to, palpitations, shortness of breath, chest pain, fatigue, left ventricular dysfunction, or other symptoms or any combination of the above
  5. Patients whose AF has been to at least one antiarrhythmic drug
  6. At least one episode of AF must have been documented by , holter, loop recorder, telemetry, trans-telephonic monitor or implanted device within the last 2 years from enrolment
  7. Patients must be able and willing to provide written to participate in the study

Exclusion criteria

Exclusion Criteria:

  1. Patients with paroxysmal AF (no episodes lasting > 7 days)
  2. Patients with early persistent AF, sustained episode ≤ 3 months
  3. Patients with very long lasting persistent AF (episodes lasting > 3 years)
  4. Patients with CHA2DS2-VASc score of 0.
  5. Patients for whom cardioversion or sinus rhythm will never be attempted/pursued
  6. Patients with AF felt to be secondary to an obvious reversible cause
  7. Patients with to oral anticoagulation or systemic anticoagulation with heparin
  8. Patients with left atrial diameter > 60 mm in the parasternal long axis view
  9. Patients who are pregnant
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
617 participants (actual)

Study arms

  • Active comparator
    PV antral isolation alone (PVAI)

    PV antral isolation alone (PVAI)

    Procedure: Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI)

  • Active comparator
    PV antral isolation plus ablation of drivers

    PV antral isolation plus ablation of drivers (PVAI+drivers)

    Procedure: Pulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers)

  • Active comparator
    PV antral isolation plus isolation of posterior wall

    PV antral isolation plus isolation of LA posterior wall (PVAI+Box)

    Procedure: Pulmonary Vein Antrum Isolation Plus Box Isolation of Posterior Wall (PVAI+box)

Interventions

  • ProcedureWide Circumferential Pulmonary Vein Antrum Isolation (PVAI)

    Standard PVI

  • ProcedurePulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers)

    Standard PVI + Ablation of drivers in LA and RA

  • ProcedurePulmonary Vein Antrum Isolation Plus Box Isolation of Posterior Wall (PVAI+box)

    Standard PVI + Electrical isolation of the posterior wall of the left atrium

06

What researchers measure

Primary outcomes

  1. Freedom from documented atrial arrhythmia ≥ 30 seconds at 18 months after one ablation procedure on or off antiarrhythmic medications (AAM).

    Time frame: 18 months

Secondary outcomes

  1. Freedom from documented AF > 30 seconds at 18 months after one procedure on or off AAM

    Time frame: 18 months

  2. Freedom from documented AF > 30 seconds at 18 months after one or more procedures on or off AAM

    Time frame: 18 months

  3. Freedom from documented atrial arrhythmia > 30 seconds at 18 months after one or more procedures on or off AAM

    Time frame: 18 months

  4. Freedom from documented AF > 30 seconds at 18 months after one procedure off AAM

    Time frame: 18 months

  5. Freedom from documented atrial arrhythmia > 30 seconds at 18 months after one procedure off AAM

    Time frame: 18 months

  6. Freedom from documented AF > 30 seconds at 18 months after one or more procedures off AAM

    Time frame: 18 months

  7. Freedom from documented atrial arrhythmia > 30 seconds after one or more procedures off AAM

    Time frame: 18 months

  8. Freedom from documented symptomatic AF > 30 seconds at 18 months after one procedure on or off AAM

    Time frame: 18 months

  9. Freedom from documented symptomatic atrial arrhythmia > 30 seconds after one procedure on or off AAM

    Time frame: 18 months

  10. Each of the above success measures stratified by CHA2DS2-VASc score

    Time frame: 18 months

  11. Incidence of peri-procedural complications including stroke, PV stenosis, cardiac perforation, esophageal injury, phrenic nerve palsy, and death

    Time frame: 18 months

  12. Procedure duration

    Time frame: 18 months

  13. Fluoroscopy time (dose)

    Time frame: 18 months

  14. Radiofrequency time

    Time frame: 18 months

  15. Number of repeat procedures

    Time frame: 18 months

  16. Effect of each strategy on AF cycle length changes and AF termination

    Time frame: 18 months

  17. Correlation of acute AF termination on long-term procedural outcome

    Time frame: 18 months

  18. Quality of life measurements during follow-up using AFEQT questionnaire

    AFEQT questionnaires will be used at baseline, 6, 12 and 18 months

    Time frame: 6-12-18 months

  19. Quality of life measurements during follow-up using SF12 questionnaires

    SF36 questionnaires will be used at baseline, 6, 12 and 18 months

    Time frame: 6-12-18 months

  20. Change in AF burden post-ablation procedure (% of time in AF)

    Time frame: 18 months

07

Study locations

32 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Sep 2027, 75 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 75 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2020
First posted
Jun 11, 2020
StartActual
Jun 1, 2021
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2027
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04428944
Responsible party
Atul Verma (Cardiologist electrophysiologist, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Jun 11, 2020
Start date
Jun 1, 2021
Primary completion
Sep 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
May 8, 2026

Study contacts

Atul Verma, Dr.
principal investigator · McGill University Health Centre/Research Institute of the McGill University Health Centre
Laurent Macle, Dr.
principal investigator · Montreal Heart Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion